Post by
jtcommon on Oct 22, 2015 8:21pm
SP Recovery
There is now a divergent between the story of CXR and VXR. CXR had been mistakenly labelled as "baby Valeant" for no other reason than they are both Canadian integrated healthcare companies. But the similarity ends there.
Concordia has a model that buys products. The completed acquisition of Amdipharm Mercury has provided Concordia a global platform that gives it a strong footprint in over 100 countries selling over 200 products. Further, it is now in a unique position to benefit from such a platform to further acquire global legacy products from biopharmaecutical makers such as Novartis and GSK. I would say that the future of the company is bright -- but you know that already.
-JT